Related Experiment Videos
Schizophrenia: elevated mRNA for dopamine D2(Longer) receptors in frontal cortex
T Tallerico1, G Novak, I S Liu
1Department of Psychiatry, Faculty of Medicine, Medical Science Building, University of Toronto, Toronto, Canada M5S 1A8.
Brain Research. Molecular Brain Research
|March 14, 2001
Summary
Dopamine D2 receptor mRNA, including the D2(Longer) form, is elevated in the frontal cortex of schizophrenia patients. This finding suggests a potential link between dopamine D2 receptor changes and schizophrenia itself.
Area of Science:
- Neuroscience
- Psychiatry
- Molecular Biology
Background:
- Dopamine D2 receptors are key targets for antipsychotic medications.
- Previous research suggests elevated D2 receptors in schizophrenia.
- Understanding D2 receptor subtypes is crucial for schizophrenia treatment.
Purpose of the Study:
- To investigate the mRNA levels of three dopamine D2 receptor forms in post-mortem brains of schizophrenia patients.
- To specifically examine the D2(Longer) mRNA variant.
Main Methods:
- Quantitative competitive reverse transcriptase-polymerase chain reaction (RT-PCR) was employed.
- Analysis focused on post-mortem frontal cortex tissues from schizophrenia patients and controls.
Main Results:
- D2(Longer) mRNA levels were significantly higher in the frontal cortex of schizophrenia patients compared to controls.
- mRNA concentrations for D2(Long) and D2(Short) were also elevated in the frontal cortex.
- Elevated mRNA levels were observed regardless of antipsychotic medication history.
Conclusions:
- The increased expression of D2(Longer), D2(Long), and D2(Short) mRNA in the frontal cortex may be associated with schizophrenia.
- These findings suggest a potential disease-related alteration in dopamine D2 receptor expression.